polymerase II, the pri-miRNAs contain cap structures, as well as poly-adenylated (poly-(A)) tail [2] . However, further research has revealed that miRNA can be also a product of RNA polymerase III, as it is for the largest human miRNA cluster C19MC, located on chromosome 19, and comprised of 43 miRNA [3] . In the nucleus, an RNA polymerase III family enzyme Drosha processes pri-miRNA into a ~70 nucleotide precursor hairpin miRNA (pre-miRNA). Active Drosha forms complexes with dsRNA-binding proteins (dsRBP) such as DiGeorge syndrome region 8 (DGCR8). This protein-RNA complex is called the Microprocessor [4] . After the cleavage, the ~70 nucleotide pre-miRNA is exported to the cytoplasm via exportin-5 in cooperation with Ras-related nuclear protein (Ran) and GTP [5] , and cleaved by another RNA polymerase III family enzyme -Dicer, to a ~22 nucleotide duplex of miRNA:miRNA * [6] . Dicer cooperates with the Ago argonaute proteins, which are hydrolytic RNAse (RNAse H)-like endonucleases that cleave the 3' end of some pre-miRNA, and transactivation-responsible RNAbinding protein (TRBP). The mature miRNA duplex can be separated, and one strand (the guide strand) binds to the miRNA-induced silencing complex (miRISC), whereas the other strand (passenger strand or miRNA * ) is usually degraded. However, recent research has revealed that many miRNA * (actually, when 2 active miRNAs originate from the same pre-miRNA, they are denoted as -5p or -3p, dependent of the RNA strand end they are processed from) are stable, mature miRNA molecules with abundant expression and regular silencing activity [7] . The miRISC is composed of an Argonaute family protein, which is a catalytically-active RNAse in the complex, GW182 (a protein of 182 kDa with many glycine-tryptophan repeats), that acts as a downstream effector of the miRNA-mediated repression and orchestrates target mRNA deadenylation, and other auxilliary proteins [8] . A slightly different method of biogenesis is typical for miRtrons, specific miRNA that are located in the introns of the miRNA encoding host genes. They are generated as pre-miRNA directly from the mRNA splicing, therefore, the step involving Drosha cleavage is omitted [9, 10] . Some miRNA can be processed directly from exons of the protein-coding mRNA during mRNA splicing [11] .
The N-terminal end of GW182 interacts with the Ago2 protein, and the C-terminal interacts with a poly[A]-binding protein (PABP) and recruits deadenylases CCR4 and CAF1 [12] . Mature miRNA binds to the target mRNA 3' untranslated region (3'-UTR) with the miRNA seed region (located at nucleotides 2-8) providing the biggest pairing specificity [13] . When there is ideal or nearly ideal complementarity between the miRNA seed sequence and the target mRNA 3'-UTR sequence, the mRNA undergoes deadenylation by deacetylases CCR4 and CAF1, and subsequent degradation by Dicer RNAse [14] . In the case of a degenerated pairing, the mRNA is not degraded, but its translation is blocked [15] . Recent findings indicate that some miRNA are also able to activate mRNA translation by binding to the 5'-UTR of target mRNA [16, 17] .
Cancer stem cells
Cancer stem cells are responsible for tumor formation and progression. They possess the ability to self-renew and give rise to diverse cells that are able to differentiate. Cancer stem cells can arise from mutations of normal stem cells [18] , however, they can emerge in other ways [19] . It has been demonstrated that differentiated somatic cells can undergo de-differentiation to yield stem-like cells that reactivate pathways responsible for self-renewal, and are associated with malignant transformation [20, 21] . Normal embryonic cells and cancer stem cells share the same cellular pathways and properties that orchestrate self-renewal. Active Wnt/β-catenin, Notch or Hedgehog signaling controls the self-renewal of hematopoietic and mammary stem cells, and their dysregulation may be an early key event leading to carcinogenesis [22, 23] . Alterations in Wnt signaling are observed in the early steps of colon cancer tumorigenesis; Hedgehog signaling defects are observed in human pancreatic, gastric, prostate and breast carcinomas [24, 25] . Notch signaling is aberrant in T-cell acute lymphoblastic leukemia (T-ALL), and breast cancer [26, 27] . Alternatively, cancer stem cells can be generated by the fusion of mutated somatic cells with normal stem cells [28] . In general, tumors contain cellular components and properties that display normal stem cells. Self-renewal drives tumorigenesis and aberrant differentiation contributes to tumor phenotypic heterogeneity.
To date, two theories of cancer development exist: a stochastic model states that all tumor cells are able to form tumors and grow progressively via the process of random mutation and clonal selection [29] , and the cancer stem cells model, which states that only a small subset of tumor cells is tumorigenic, and this subset is characterized by their capacity to self-renew and differentiate [30] . However, these two models are not mutually exclusive, since cancer stem cells can also accumulate mutations, which leads to an increased heterogeneity of the tumor.
The current definition of cancer stem cells comes from the American Association of Cancer Research (AACR) meeting in 2006, and is as follows: 'a cancer stem cell is a cell within a tumor that possesses the capacity to self-renew and to cause the heterogeneous lineages of cancer that comprise the tumor' [19] .
The first CSC were identified in acute myeloid leukemia (AML), where a small subset of tumor cells with the cell surface phenotype CD34 + CD38
-(comprising up to 1% of the total population) could induce leukemia in a NOD/SCID (non-obese diabetic with severe combined immunodeficiency disease) mouse model, whereas cells negative to CD34 failed to initiate cancer [31, 32] [34] . Cells with this phenotype also expressed the Oct4 transcription factor, which is a stem cell marker, and VEGF (vascular endothelial growth factor), which turned these tumor mammospheres into highly angiogenic cultures [35] . Subsequently, cancer stem cells were found in other solid malignancies, such as colon [36] , medulloblastoma and glioblastoma tumors of the brain [37] , hepatocellular carcinoma [38] and melanoma [39] , to name a few. The identification and isolation of cancer stem cells is problematic, because several surface stem cell markers may be shared by multiple tumor types types (Table 1) .
For instance, CD133 (prominin), a cholesterolinteracting transmembrane glycoprotein is typical for prostate [40] , pancreatic [41] , and melanoma cancer stem cells [42] , and CD44 is present on AML [43] , prostate [44] and pancreatic cancer stem cells [45] . In the case of melanoma, although the existence of melanoma initiating cells (MICs) with the stem cell phenotype was demonstrated, data regarding typical stem cell marker(s) for melanoma are inconclusive, and no markers distinguishing tumorigenic from nontumorigenic melanoma populations have been identified so far [46] . Melanoma stem-like cells can grow nonadherently as melanospheres in vitro, and this kind of growth can be achieved by the external stimuli in a cancer microenvironment [47] . These motile and invasive cells are weakly pigmented [48] [80] ; lung cancer [79] miR-128 BMI-1 glioma [83] miR-145 Oct4, Sox2, c-Myc prostate cancer [87] , melanoma [88] miR-150 c-Myb, Bcl-2, cyclin D1 liver cancer [103] miR-17cluster c-Myc, E2F, Rb, cyclin D1 breast cancer [108] ; lung cancer [109] miR-181 CDX2, GATA-6, NLK liver cancer [105] ; breast cancer [107] miR-199 HES1 medulloblastoma [100] ; ovarian cancer [101] ; and hepatocellular carcinoma [102] miR-200b Suz12 breast cancer [63] miR-200c BMI-1 breast cancer [82] miR-203 ZEB1 hepatocellular carcinoma [98] ; prostate cancer [99] miR-302 cyclin D1 skin cancers [91] mir-34 Notch, Bcl-2, CD44 pancreatic cancer [92] ; breast cancer [93] ; prostate cancer [97] stem cells are characterized with increased expression of Oct4 and Nanog transcription factors, and decreased expression of differentiation markers such as tyrosinase or Microphthalmia-associated transcription factor (MITF) [49] . Melanospheres contain an increased percentage of cells in G 0 /G 1 . In melanospheres MITF depletion promotes growth arrest due to a decrease in Cdk2 kinase and increase in p21 and p27 levels, which are transcriptional targets of MITF [50, 51] . The upregulation of p27 is a key event in the induction of the cancer stem cell phenotype mediated by MITF depletion, since p27 overexpression promotes Oct4 and Nanog increase [49] . Stem cells exist in a quiescent G 0 state, and selfrenewal properties are activated upon microenvironmental stimuli. The cell cycle is among others regulated by p16
INK4a which in turn is regulated by a polycomb-group protein BMI-1. This protein epigenetically represses the transcription of developmental Hox genes, or cell cycle regulators p16 INK4a , and p14 ARF [52] . The BMI-1-mediated downregulation of p16 modulates hematopoietic and neuronal stem cell self-renewal [53] . BMI-1 is known to be essential in regulating the self-renewal and differentiation of hematopoietic, brain and mammary stem cells [52] [53] [54] . It is also a positive regulator of epithelial-mesenchymal transition (EMT) [55] [56] [57] . BMI-1 protein is a member of the PRC1 polycomb complex that, together with PRC2, maintains cells in a repressed, non-differentiated state [58] . PRC2 is responsible for di-and tri-methylation of lysine 27 on histone H3 [59] , thereby repressing gene expression. Moreover, PRC2 is important in the maintenance of aberrant silencing of tumor suppressor genes during oncogenic transformation [60, 61] . PRC1 in turn recognizes the methylated lysine and mediates transcriptional repression of selected genes. Aberrant expression of BMI-1 (PRC1 complex element) or Suz12 (PRC2 complex element) are documented in many different types of cancer and cancer stem cells [60] [61] [62] . Ectopic expression of Suz12 is sufficient to generate breast cancer stem cells [63] .
Cancer stem cells display remarkable plasticity that enables them to switch between an epithelial phenotype (proliferating cells), and mesenchymal migrating cells that drive metastasis [64] . The switch between these two phenotypes is possible due to a reversible transition: epithelial-mesenchymal (EMT) and mesenchymalepithelial (MET). Solid tumor CSCs undergo EMT to gain the migratory phenotype, which enables them to colonize distant sites, where they subsequently regain the epithelial phenotype through MET and can establish a novel metastatic tumor [65] .
EMT is a normal cellular event during embryonic development of tissues, or wound healing. However, in normal adult cells, the pathways leading to EMT are naturally silenced. EMT in cancer cells results in the enrichment of cells with stem-like properties [66] . In cancer and cancer stem cells, aberrant Wnt signaling, or mutations of Slug, Snail or Twist transcription factors renders cells susceptible to cellular changes, such as a decrease in E-cadherin (a marker of epihelial cells), increase in vimentin and N-cadherin (mesenchymal markers), and nuclear transition of β-catenin [67] . Moreover, another inducer of EMT, transcription factor Zeb1, is also frequently overexpressed in cancer stem cells [68] .
Recent data strongly suggest that cancer stem cells are the main cause of tumor resistance to common therapies including immuno-, radio-and chemotherapy, and cancer recurrence after surgical excision of the tumor. Traditional anti-cancer therapy kills the bulk of non-tumorigenic cancer cells, whereas cancer stem cells remain mainly unaffected. These unaffected cells can cause tumor relapse. Cancer stem cells display features that increase drug-resistance, e.g. Oct4 and ABCG2 (drug efflux pump) overexpression, or aberrant PI3K and Akt signaling mediate cisplatin resistance of hepatocellular cancer stem cells, and the membrane-bound ABCB5 drug efflux pump is specific to doxorubicin in melanoma initiating cells [69, 70] . Therefore, novel, efficient CSC-targeted therapies are being elucidated. Recently, Gupta et al. [71] found a compound, salinomycin,that preferentially targeted breast cancer stem cells, which resulted in a decrease in the expression of a subset of genes linked with stemlike properties of cancer cells.
miRNA and cancer stem cells
In a wide variety of developmental processes miRNAs control cellular fate by targeting important genes for cell development, and differentiation [72] . Therefore, they are essential in normal cell maintenance. Deletion of the DICER enzyme affects self-renewal of embryonic stem cells, tissue morphogenesis and the development of B lymphocyte lineage cells [73] [74] [75] . Deletion of another important miRNA-processing enzyme, DGCR8, alters the expression of self-renewal genes in embryonic stem cells [76] . Since, the deregulation of miRNA expression or biogenesis triggers aberrant development and differentiation, miRNAs have been rapidly linked to cancer propagation via cancer stem cells (Table 2 ). The first miRNAs identified in C. elegans, Let-7 and Lin-4, were involved in the regulation of developmental processes [77] . Let-7 family members are absent in embryonic stem cells and pluripotent populations, and their expression augments after differentiation [78] . Let-7 expression is diminished in various tumors including breast and lung cancer cells [79, 80] . It turns out, that let-7 controls the switch between self-renewal and differentiation in breast cancer stem cells. Since its direct mRNA targets comprise Ras, HMGA, CDK4, cyclin D1 and other regulators of cell division [81] , re-expression of let-7 prevents tumor sphere formation in vitro and inhibits tumorigenicity in vivo [80] .
In 2009, Shimono et al. [82] analyzed the miRNA profile in CD44 + CD24 -/low tumorigenic breast cancer cells and found that the expression of 37 miRNAs was deregulated compared to non-tumorigenic breast cancer cells. The majority of these 37 miRNAs was also differentially expressed in normal human mammary stem cells, indicating, that these dysregulated miRNAs take part in the normal mammary cell developmental pathways. Among them, three clusters, miR- [82] . BMI-1 is also down-regulated by miR-128 in glioma cells [83] . Moreover, miR-200c, together with miR-141 targets Zeb-1, a major activator of EMT in colorectal and breast cancer cells [84] . Overexpression of either miRNA results in the induction of epithelial differentiation of undifferentiated cancer cells and an increase in E-cadherin expression. Expression of both miRNAs is controlled by the Zeb-1 transcription factor, indicating the existence of a loop controlling the EMT process in these cells. Moreover, inhibition of both miRNA in highly differentiated epithelial cells induced mesenchymal transition, as indicated by cell scattering, vimentin upregulation and a decrease in E-cadherin expression [84] . Another miRNA from the miR-200 family deregulated in cancer cells is miR200b. It directly targets the Suz12 mRNA, a component of the polycomb repressor complex PRC2 [63] . Loss of miR-200b promotes Suz12 expression and increases Suz12 binding to the PRC2 complex, which results in E-cadherin repression. Forced miR-200b expression in breast cancer cells, or Suz12 depletion, blocks the formation and maintenance of mammospheres [63] .
MiR-145 is a temporarily regulated miRNA during hESC differentiation. The levels of Oct4, Sox2 and KLF4 are controlled by miR-145. Ectopic expression of miR-145 disrupts the maintenance of hESC in a selfrenewal state [85] . MiR-145 is necessary and sufficient to modulate the differentiation through the Oct4/Sox2. Moreover, the miR-145 promoter is repressed by Oct4, assuring the self-renewal feedback loop [85] . MiR-145 contains a unique seed sequence conserved in all mammals. MiR-145 is augmented in the germline and mesoderm-derived tissues (uterus, ovary, testis, prostate, spleen and heart) [86] . Its expression decreases in prostate cancer cell lines, compared to normal cells, due to promoter methylation. Overexpression of miR-145 resulted in growth arrest and apoptosis of prostate cancer cells [87] . This miRNA is also downregualted in human melanoma cell lines. Ectopic expression of miR-145 resulted in growth inhibition of tumor cells, mediated by miR-145-dependent c-Myc suppression [88] .
miR-302 is another molecule highly expressed in embryonic stem cells, with decreasing expression after terminal differentiation [89] . Its expression is positively regulated by Oct4 and Sox2 [90] . The main target of miR-302 is cyclin D1. Overexpression of miR-302 converts cancer stem cells with highly-expressed stem cell markers, such as Sox2 or Nanog, towards various differentiated cells [91] .
Mir-34 targets the Notch and anti-apoptotic protein Bcl-2 in various tumors including pancreatic and breast cancer, thus inhibiting tumorisphere formation in vitro, and tumor growth in vivo [92, 93] . The expression of miR-34 is diminished by promoter methylation in melanoma, colorectal cancer and oral squamous cell carcinoma [94] . MiR-34 cooperates with p53 to orchestrate the cell cycle, proliferation or colony formation [95] . Re-expressed miR-34 induces apoptosis, however, this action can be suppressed by inactivation of p53 [96] . Expression of miR-34 antagomirs in CD44 + prostate cancer cells promoted tumor development and metastasis. Forced miR-34 expression in these cells inhibited clonogenic expansion, tumor regeneration and metastasis, directly targeting CD44 [97] . Restoration of miR-34 expression decreased a number of CD44 + /CD133
+ pancreatic cancer cells with tumorigenic capacity [92] .
MiR-203 inhibits EMT via repression of ZEB1, which is also an important regulator of the self-renewal capacity of pancreatic and colorectal cancer stem cells [68] . The expression of this miRNA is silenced by promoter methylation in hepatocellular carcinoma, and specifically attenuated in prostate cancer cells [98, 99] .
Mir-199 targets HES1, a transcription factor of the Notch pathway and its expression is dysregulated in medulloblastoma, ovarian cancer and hepatocellular carcinoma [100] [101] [102] . Overexpression of miR-199 triggered cell cycle arrest in G 2 /M phase in hepatocellular carcinoma, and decreased the amount of medulloblastoma cells with the CD133 + phenotype. Mir-150 is upregulated in CD133 + liver cancer cells. Its most important target is c-Myb, and overexpression of miR-150 diminishes the CD133 + cell number, which is accompanied with growth inhibition and tumor sphere formation. Overexpression of miR-150 also diminishes the levels of Bcl-2 and cyclin D1 in these cells [103] .
Some miRNAs are cell-type specific in action. MiR-181 is an example of a regulatory molecule, whose expression is augmented in adult differentiated B lymphocytes, compared to undifferentiated progenitor cells [104] , whereas, in hepatocellular carcinoma cells of the stem-like phenotype, miR-181 is upregulated [105] . These cells are characterized by having the expressed epithelial cell adhesion molecule (EpCAM) and α-ferroprotein (AFP). The former protein is a membrane-associated glycoprotein typical for stem cells, whereas the latter one is a plasma protein overexpressed during embryonic development. In these cells the miR-181 downregulates the hepatic transcriptional regulators of differentiation, e.g. cadual type homeobox 2 (CDX2) and GATA-6 transcription factors, or nemo-like kinase (NLK) which is an inhibitor of Wnt signaling in stem cells [105] . Forced miR-181 expression enriched the population of EpCAM + cells with liver stem cell properties, whereas miR-181 blockade reduced the number of EpCAM + cells and induced hepatic differentiation. Four members of the miR-181 family are elevated in the HCC cells. They are presumed to be the master key regulators of Wnt signaling in these cells [106] . Mir-181 is also upregulated in breast cancer stem cells [107] . This upregulation is mediated post-transcriptionally by TGF-β. TGF-β and miR-181 increase the population of breast cancer cells that can form mammospheres in suspension. The main target of miR-181 in cancer mammospheres is ataxia telangiectasia mutated (ATM), a serine/threonine kinase that activates checkpoint kinase 2 (CHK2) as a response to DNA strand breaks. Under TGF-β induction, ATM expression is reduced. Overexpression of miR-181 or depletion of ATM or its substrate CHK2 is sufficient to induce mammospheres formation.
Another miRNA that acts differently in various cell types is the miR-17 cluster composed of 6 miRNA. This cluster inhibits tumor growth in breast cancer cells [108] , but promotes tumorigenesis in lung cancer [109] . miRNAs of this cluster target transcription factors responsible for cell cycle control (c-myc, E2F, Rb) and cyclin D1 [108] .
Introducing miRNA-targeted therapy
The problem of tumor recurrence caused by ineffective treatment of tumorigenic cells with a stem-like phenotype prompted scientists to elaborate therapies that directly target cancer stem cells. Since the "stemness" of these cells is mainly controlled by miRNAs, several modes of action against aberrantly-expressed miRNAs are being verified. In the case of downregulated tumor suppressor miRNAs, their precursors or mimetics should be introduced. The introduction of miRNAs that are downregulated in cancer cells is possible via transfection or transduction of pri-miRNA transgene, pre-miRNA double strand RNA duplex, siRNA or shRNA. Using these methods, let-7 miRNA has been reexpressed in lung cancer [81, 110, 111] causing reduction in cancer cells proliferation in vitro and regression of tumor in vivo. Also in hepatocellular hepatoma, the delivery of miR26a into mouse xenografts induced tumor regression [112] .
The transfection method provides transient (up to 30 days) introduction of miRNAs, however, the efficacy of treatment is limited by inefficient delivery or degradation of these molecules. The most efficient way of introducing deficient miRNAs or miRNA mimics is via infection with viral vectors containing shRNA that can be processed into natural miRNAs [110, 113] . For instance, Ji and colleagues transfected the miR-34a mimetic to gastric cancer tumorispheres by using a stably infected miR-34a-containing lentivirus [114] . Stable expression of miR-34a using the lentiviral system caused inhibition of cancer growth and tumorispheres formation in vitro. This effect was achieved by cell accumulation in the G 1 phase and caspase-3 activation.
On the other hand, miRNAs upregulated in cancer cells (oncomiRs) can be inhibited with antisense oligonucleotides (antagomiRs). The antagomiRs should block the tumorigenic effect of targeted oncomirs, resulting in a decrease in cancer progression [115] . For instance, introduction of anti-miR-21 into a human glioma in vitro model or into glioma mouse xenografts decreased tumor formation, migration and invasiveness [116] , and treatment of breast cancer cells with antimiR-132 suppressed angiogenesis and decreased tumor xenografts in mouse [117] .
To improve the efficacy of antisense oligonucleotides targeting oncogenic miRNAs, several chemical modifications has been introduced. First modified RNAs (2'-O-methyl ribose-modified RNAs conjugated with dextran polymers) were introduced into C. elegans [118] . Cholesterol-conjugated antisense oligonucleotides, in turn, can be easily introduced into mammalian cells and distributed throughout the whole organism via [119] . Better results were demonstrated with locked nucleic acids (LNA). In these oligonucleotide variants, the ribose ring is modified with an additional bond between the 2'-oxygen and 4'-carbon. This modification significantly increases melting temperature and stabilization of the RNA duplexes, specificity for target miRNAs, and resistance to endonucleases [120] . The mentioned methods showed promising results in in vitro studies, however, the biggest drawbacks of this approach are to specifically deliver antagomiRs or miRNA mimics to cancer cells, and to obtain permanent therapeutic effect. Several ways developed to deliver small interfering RNA (siRNA), including cationic liposomes, virus-based vectors, or intranasal administration for lung cancers are described in detail in the paper of Oh and colleagues [121] .
Conclusions
This review summarizes the recent state of knowledge regarding miRNA control of the stem-like properties of cancer cells and underpins the role of dysregulated miRNA pathways in cancer development and progression. Recent studies, both in vitro and in vivo, revealed the significance of the miRNA-controlled pathways in maintaining the stem-like phenotype of cancer cells. Moreover, therapeutic intervention in these pathways could overcome drug resistance, decrease tumor burden, prevent metastasis and promote apoptosis. The miRNA-targeted therapies that are slowly, but steadily, being developed and improved upon, are the hope for people suffering from highly malignant tumors. In fact, several antisense oligonucleotides are currently in clinical trials, and many more show promising results in non-human primates [122] .
